Obstructive Sleep Apnoea (OSA) treatment innovator, Oventus Medical Ltd (the Company, ASX: OVN) is pleased to release its Appendix 4C and quarterly business activities review for the three month period ended 30 June 2020 (Q4 FY2020).
Oventus Founder and CEO, Dr Chris Hart commented, “When the impact of COVID-19 became clear in March, Oventus moved quickly to protect our customers and business plan, reduce operating costs, adapt workflows and processes to enable business continuation.
For more information, download the attached PDF.
Download this document
